剑桥大学团队11月13日论文:微流控平台nanoFLIM打通体外、细胞与体内三级筛选,发现淀粉样β聚集抑制剂

英国剑桥大学团队11月13日在《Nature Communications》发表论文,报告一套名为 nanoFLIM 的微流控荧光寿命筛选平台,用于发现抑制淀粉样β蛋白聚集的化合物。抑制淀粉样β(1-42)聚集被视为开发阿尔茨海默病疾病修饰疗法的一条路径。
论文指出,迄今已有200多项进入后期的药物开发项目未能找到足够有效的抑制剂,失败原因之一是现有体外化合物筛选与体内验证方法的局限。nanoFLIM 把荧光寿命成像与微流控结合,在同一平台思路下衔接不同层级的检测。
团队用该平台识别并验证聚集抑制剂,验证环节覆盖体外、细胞内与体内三个层级,其中体内验证使用了秀丽隐杆线虫模型。论文作者来自剑桥大学化学系、生物化学系与化学工程和生物技术系等单位,通讯作者包括 David R. Spring、Florian Hollfelder 与 Gabriele S. Kaminski Schierle。
该研究为方法学论文,报告的是筛选平台本身及其发现抑制剂的能力,所涉化合物尚处早期研究阶段,论文未报告人体临床试验结果。
University of Cambridge Team on November 13: Microfluidic Platform nanoFLIM Bridges In Vitro, In Cellulo and In Vivo Screening to Find Amyloid β Aggregation Inhibitors
A University of Cambridge team published a paper on November 13 in Nature Communications reporting nanoFLIM, a microfluidic fluorescence lifetime screening platform designed to discover compounds that inhibit amyloid β aggregation. Inhibiting the aggregation of amyloid β (1-42) is considered a promising strategy for developing disease-modifying Alzheimer's disease therapeutics.
The paper notes that more than 200 advanced drug development campaigns have so far failed to identify sufficiently efficacious inhibitors, a failure it attributes in part to limitations in current in vitro compound screening and in vivo validation assays. nanoFLIM combines fluorescence lifetime imaging with microfluidics to bridge those formats.
The team used the platform to identify and validate aggregation inhibitors across in vitro, in cellulo and in vivo settings, with the in vivo validation carried out in the nematode C. elegans. The authors are based in Cambridge's departments of Chemistry, Biochemistry, and Chemical Engineering and Biotechnology, among others, and the corresponding authors include David R. Spring, Florian Hollfelder and Gabriele S. Kaminski Schierle.
The study is a methods paper. It reports the screening platform and its ability to discover inhibitors; the compounds involved remain at an early research stage, and the paper reports no human clinical trial results.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:Amyloid-plaque formation-big.jpg — Source: ADEAR (Alzheimer's Disease Education and Referral Center); derivative work: Garrondo. Licensing: Public domain.
GSM Global · 本篇英文版 English edition of this story

